Aria des инструкция на русском

See also:
What are the possible side effects of Aria-des 2,5 mg/5 ml?

The following adverse reactions are discussed in greater detail in other sections of the label:

• Hypersensitivity reactions.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adults and Adolescents

Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2834 patients ages 12 years or older received Aria-des 2,5 mg/5 ml tablets at doses of 2.5 mg to 20 mg daily, of whom 1655 patients received the recommended daily dose of 5 mg. In patients receiving 5 mg daily, the rate of adverse events was similar between Aria-des 2,5 mg/5 ml and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the Aria-des 2,5 mg/5 ml group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving Aria-des 2,5 mg/5 ml. All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of Aria-des 2,5 mg/5 ml tablets (5 mg once daily), and that were more common with Aria-des 2,5 mg/5 ml tablets than placebo, are listed in Table 1.

The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in Aria-des 2,5 mg/5 ml and placebo-treated patients.

There were no differences in adverse events for subgroups of patients as defined by gender, age, or race.

Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic idiopathic urticaria, 211 patients ages 12 years or older received Aria-des 2,5 mg/5 ml tablets and 205 received placebo. Adverse events that were reported by greater than or equal to 2% of patients who received Aria-des 2,5 mg/5 ml tablets and that were more common with Aria-des 2,5 mg/5 ml than placebo were (rates for Aria-des 2,5 mg/5 ml and placebo, respectively): headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%), pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).

Pediatrics

Two hundred and forty-six pediatric subjects 6 months to 11 years of age received Aria-des 2,5 mg/5 ml

Oral Solution for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1.0 mg once a day.

In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects.

In subjects 2 to 5 years of age, adverse events reported for Aria-des 2,5 mg/5 ml and placebo in at least 2 percent of subjects receiving Aria-des 2,5 mg/5 ml

Oral Solution and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%) and varicella (3.6%, 0%).

In subjects 12 months to 23 months of age, adverse events reported for the Aria-des 2,5 mg/5 ml product and placebo in at least 2 percent of subjects receiving Aria-des 2,5 mg/5 ml

Oral Solution and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%).

In subjects 6 months to 11 months of age, adverse events reported for Aria-des 2,5 mg/5 ml and placebo in at least 2 percent of subjects receiving Aria-des 2,5 mg/5 ml

Oral Solution and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3.0%, 1.6%), and nausea (3.0%, 0%).

There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pediatric subjects receiving Aria-des 2,5 mg/5 ml

Oral Solution in the clinical trials discontinued treatment because of an adverse event.

Post-Marketing Experience

Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following spontaneous adverse events have been reported during the marketing of Aria-des 2,5 mg/5 ml: tachycardia, palpitations, rare cases of hypersensitivity reactions (such as rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures, and elevated liver enzymes including bilirubin, and very rarely, hepatitis.

Description

At the core of Aria-Des Syrup lies its active ingredient – Desloratadine. This potent compound is the driving force behind Aria-des 2.5 mg/5 ml, particularly in Turkey.

Allergies and Beyond

Aria-Des Syrup finds its utility in addressing a spectrum of allergy-related concerns, encompassing:

Seasonal Allergic Rhinitis

For patients aged 12 and older, Aria-Des Syrup stands as a reliable relief for both nasal and non-nasal symptoms induced by seasonal allergic rhinitis.

Perennial Allergic Rhinitis

The nasal and non-nasal symptoms associated with perennial allergic rhinitis in patients aged 12 and older meet their match with Aria-Des Syrup.

Chronic Idiopathic Urticaria

In the battle against chronic idiopathic urticaria, Aria-Des Syrup emerges as a symbol of symptomatic relief. It curbs pruritus, reduces the number and size of hives, primarily in patients aged 12 and older.

Antihistamine

Aria-Des Syrup operates as an antihistamine, reining in the effects of histamine, a natural chemical present in the human body. Histamine is known to orchestrate the unpleasant symphony of symptoms like sneezing, itching, watery eyes, and a runny nose.

Usage Guidelines

When venturing into the territory of Aria-Des Syrup, adherence to your doctor’s directives is key. The tablet dissolves rapidly, making it effortless to consume with a mere touch of saliva. The oral disintegrating tablets, branded as Aria-des 2.5 mg/5 ml, offer flexibility – they can be taken with or without water.

Side Effects

While the active ingredient Desloratadine steers Aria-Des Syrup towards alleviating allergies, it may also introduce certain side effects. It’s important to note that not everyone who embarks on this medication journey will encounter these side effects. However, being prepared is prudent.

Common Side Effects

The common side effects typically associated with Aria-Des Syrup include:

Side Effects in Children

Children under the age of two may exhibit side effects distinct from those in adults. The most common side effects in this age group include:

Should any of these side effects persist or worsen or if any unlisted side effects make an appearance, swift communication with your healthcare provider is highly recommended. Remember that your doctor prescribed this medication with the understanding that its benefits far outweigh the potential side effects. Many individuals who employ this medication do so without encountering any significant side effects.

Over-the-Counter Possibilities

Aria-Des Syrup, much like other medications, may find itself available over-the-counter in select regions. Nevertheless, the accessibility of this medication in such a manner is subject to the regulations of individual countries and the specific product in question. When contemplating over-the-counter availability, the counsel of a healthcare professional or pharmacist is invaluable. It’s important to underline that even if a medication is accessible over-the-counter, responsible usage in accordance with professional guidance remains paramount.

Aria-Des Syrup Benefits

The journey into the world of Aria-Des Syrup reveals a multitude of advantages, primarily attributed to its active ingredient, Desloratadine:

Allergy Relief

For individuals grappling with the discomfort of allergies, including symptoms such as sneezing, watery eyes, and a runny nose, Aria-Des Syrup takes center stage. It exerts control over these symptoms and extends a hand of relief to those plagued by allergies.

Resolving Skin Reactions

Aria-Des Syrup does not confine its utility to respiratory allergies alone. It also addresses skin hives and itching in individuals dealing with chronic skin reactions. This aspect significantly enhances the quality of life for those enduring such conditions.

A Non-Drowsy Companion

One of the remarkable traits of Aria-Des Syrup is its non-drowsy nature. Unlike certain antihistamines that can induce drowsiness, this medication empowers individuals to carry on with their daily activities without the encumbrance of drowsiness.

Rhinitis Reconciliation

Aria-Des Syrup emerges as a versatile treatment option, effectively addressing both seasonal allergic rhinitis and perennial allergic rhinitis. This inclusivity enhances its appeal as a remedy for diverse forms of rhinitis.

Relief for Chronic Idiopathic Urticaria

For patients aged 12 and older grappling with chronic idiopathic urticaria, Aria-Des Syrup is a ray of hope. It effectively provides relief from pruritus, reduces the number of hives, and the size of hives, alleviating the discomfort associated with this condition.

Dosing Decisions

The recommended dosage of Aria-Des Syrup is contingent upon the patient’s age:

Children 6 to 11 Months of Age

For the youngest patients, aged 6 to 11 months, the prescribed dose is ½ teaspoonful (1.25 mg in 2.5 mL) once daily.

Children 12 Months to 5 Years of Age

Younger children, aged 12 months to 5 years, should take 1 teaspoonful (2.5 mg in 5 mL) once daily.

Children 6 to 11 Years of Age

For children aged 6 to 11 years, the appropriate dosage is 1 teaspoonful (2.5 mg in 5 mL) once daily.

Children 12 Years and Older and Adults

Adolescents aged 12 years and older, as well as adults, are advised to take one 2.5-mg tablet once daily or 2 teaspoonfuls (5 mg in 10 mL) once daily.

These are general recommendations, and it’s crucial to recognize that the precise dosage may vary according to an individual’s condition and their response to the medication. Therefore, it’s imperative to engage in a comprehensive discussion with a healthcare professional to ascertain the most fitting course of action.

The Duration of Use

The duration of Aria-Des Syrup treatment is a nuanced aspect, subject to the patient’s specific condition and their response to the medication. Following the counsel provided by your healthcare professional is pivotal. Certain conditions may necessitate short-term usage, while others may require a more prolonged treatment regimen. As always, the counsel of your healthcare professional should guide your path.

Conclusion

In conclusion, Aria-Des Syrup emerges as a versatile solution for a range of allergy-related issues, offering a non-drowsy, effective approach to managing symptoms. Nevertheless, it’s imperative to underscore that responsible usage under the guidance of a healthcare professional remains the cornerstone of this journey. While this comprehensive guide endeavors to provide valuable insights, it should not be considered a substitute for professional medical consultation.

For personalized medical guidance and precise information, engaging in a consultation with a healthcare provider is indispensable.

Use the form below to report an error

Please answer the questions as thoroughly and accurately as possible. Your answers will help us better understand what kind of mistakes happen, why and where they happen, and in the end the purpose is to build a better archive to guide researchers and professionals around the world.

The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. always seek the advice for your physician or another qualified health provider with any questions you may have regarding a medical condition. Always remember to

1. Ask your own doctor for medical advice.
2. Names, brands, and dosage may differ between countries.
3. When not feeling well, or experiencing side effects always contact your own doctor.

Cyberchondria

The truth is that when we’re sick, or worried about getting sick, the internet won’t help.

According to Wikipedia, cyberchondria is a mental disorder consisting in the desire to independently make a diagnosis based on the symptoms of diseases described on Internet sites.

Why you can’t look for symptoms on the Internet

If diagnoses could be made simply from a textbook or an article on a website, we would all be doctors and treat ourselves. Nothing can replace the experience and knowledge of specially trained people. As in any field, in medicine there are unscrupulous specialists, differences of opinion, inaccurate diagnoses and incorrect test results.

Препарат Эридез — антигистаминное средство для системного применения. 
Дезлоратадин является селективным блокатором периферических Н1-рецепторов, не оказывает седативного эффекта. Дезлоратадин является первичным активным метаболитом лоратадина. После приема дезлоратадин селективно блокирует периферические Н1-гистаминовые рецепторы и не проникает через гематоэнцефалический барьер.
Кроме антигистаминного активности, дезлоратадин производит противоаллергическое и противовоспалительное действие. Установлено, что дезлоратадин подавляет каскад различных реакций, лежащих в основе развития аллергического воспаления, а именно:
— выделение провоспалительных цитокинов, включая ИЛ-4, ИЛ-6, ИЛ-8, ИЛ-13;
— выделение провоспалительных хемокинов, таких как RANTES;
— продукцию супероксидного аниона активированными полиморфноядерными нейтрофилами;
— адгезию и хемотаксис эозинофилов;
— экспрессию молекул адгезии, таких как Р-селектина;
— IgE-зависимое выделение гистамина, простагландина D2 и лейкотриена С4;
— острый аллергический бронхоспазм в исследованиях на животных.
Дезлоратадин не проникает через гематоэнцефалический барьер, не влияет на психомоторную функцию при приеме дозы до 7,5 мг.
Дезлоратадин начинает определяться в плазме в течение 30 мин после приема.
Максимальная концентрация дезлоратадина в плазме достигается в среднем через 3:00, период полувыведения составляет в среднем 27 часов. Степень кумуляции дезлоратадина соответствует его периода полувыведения (примерно 27 часов) и кратности применения (1 раз в сутки). Биодоступность дезлоратадина пропорциональна дозе в диапазоне от 5 до 20 мг.
Дезлоратадин умеренно (83-87%) связывается с белками плазмы. При применении дезлоратадина в дозе от 5 до 20 мг 1 раз в сутки в течение 14 дней признаков клинически значимой кумуляции препарата не выявлено.
Еда (жирный высококалорийный завтрак) или грейпфрутовый сок не влияет на распределение дезлоратадина.

Показания к применению:
Препарат Эридез предназначен для быстрого устранения аллергических симптомов и аллергического ринита (таких как чихание, выделения из носа, зуд, отек и заложенность носа, а также зуд, слезотечение и покраснение глаз, зуд в области неба и кашель) для устранения симптомов, связанных с крапивницей, зуда и сыпи.

Способ применения:
Еридез предназначен для перорального приема. Взрослые и дети старше 12 лет по 1 таблетке (5 мг) 1 раз в день независимо от приема пищи. Таблетку нужно глотать целиком, запивая водой. Еридез желательно принимать регулярно, в одно и то же время суток.
Продолжительность лечения определяется тяжестью и течением заболевания.
Терапию интермиттирующего аллергического ринита (наличие симптомов менее 4 дней в неделю или менее 4 недель) необходимо проводить с учетом данных анамнеза: прекратить после исчезновения симптомов и восстановить после повторного их возникновения.
При персистирующем аллергическом рините (наличие симптомов более 4 дней в неделю или более 4 недель) необходимо продолжать лечение в течение всего периода контакта с аллергеном.

Побочные действия:
При применении препарата Эридез частыми нежелательными явлениями были повышенная утомляемость, сухость во рту, головная боль.
Очень редко сообщалось о реакции гиперчувствительности (включая анафилаксии и сыпь), тахикардию, сердцебиение, психомоторную гиперактивность, судороги, повышение активности печеночных ферментов, повышение уровня билирубина, развитие гепатита.
В случае появления любых нежелательных явлений больному необходимо посоветоваться с врачом.

Противопоказания:
Противопоказаниями к применению препарата Эридез являются: гиперчувствительность к дезлоратадина или лоратадина; беременность, период кормления грудью, дети до 12 лет (для данной лекарственной формы).
С осторожностью назначают пациентам с почечной и печеночной недостаточностью.

Беременность:
Безопасность применения Еридеза у беременных не установлена, поэтому его не рекомендуется назначать в период беременности.
Дезлоратадин проникает в грудное молоко, поэтому препарат не следует назначать женщинам в период кормления грудью.

Взаимодействие с другими лекарственными средствами:
Если Вы принимаете любые другие лекарственные средства, обязательно сообщите об этом врачу.
Клинически значимых изменений в плазменной концентрации дезлоратадина при неоднократном совместном применении с кетоконазолом, эритромицином, азитромицином, флуоксетином, циметидином обнаружено не было. В связи с тем, что фермент, отвечающий за метаболизм дезлоратадина, не установлен, взаимодействие с другими лекарственными средствами полностью исключить невозможно.

Передозировка:
При случайном приеме больших доз Еридеза возможно усиление побочных эффектов — повышенная утомляемость, сухость во рту, головная боль, тахикардия.
Лечение. Промывание желудка, прием активированного угля, симптоматическая терапия. Дезлоратадин не удаляется при гемодиализе; эффективность перитонеального диализа не установлена.

Условия хранения:
Хранить в оригинальной упаковке при температуре не выше 25 ° С.
Хранить в недоступном для детей месте.

Форма выпуска:
Эридез — таблетки, покрытые оболочкой.
Упаковка: по 10 таблеток в контурной ячейковой упаковке; по 1 контурной ячейковой упаковке в пачке.

Состав:
1 таблетка Эридез содержит дезлоратадина 5 мг.
Вспомогательные вещества: маннит (Е 421), крахмал кукурузный, гидроксипропилцеллюлоза низкозамещенная, тальк, кальция фосфат, гипромеллоза (гидроксипропилметилцеллюлоза), титана диоксид (Е 171), пропиленгликоль, железа оксид красный (Е172), железа оксид желтый (Е 172).

Дополнительно:
Дезлоратадин не усиливает такие эффекты алкоголя как нарушение психомоторной функции и сонливость. Результаты психомоторных тестов существенно не отличались у пациентов, получавших дезлоратадин и плацебо отдельно или вместе с алкоголем.
Способность влиять на скорость реакции при управлении автотранспортом или другими механизмами
Влияния дезлоратадина на управление автомобилем или работу со сложными техническими устройствами не отмечалось.
Эффективность и безопасность дезлоратадина в форме таблеток у детей в возрасте до 12 лет не исследовалась.